Literature DB >> 27214072

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.

J Kothari1, M Foley1, K S Peggs2, S Mackenzie1, K Thomson1, E Morris3, K M Ardeshna1, A E Virchis1, D C Linch2, J Lambert1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27214072     DOI： 10.1038/bmt.2016.134

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.

Authors:  M D Caballero; V Rubio; J Rifon; I Heras; R García-Sanz; L Vázquez; B Vidriales; M C del Cañizo; M Corral; M Gonzalez; A León; E Jean-Paul; E Rocha; J M Moraleda; J F San Miguel
Journal:  Bone Marrow Transplant       Date:  1997-09       Impact factor: 5.483

2.  BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Authors:  Giuseppe Visani; Lara Malerba; Pietro Maria Stefani; Saveria Capria; Piero Galieni; Francesco Gaudio; Giorgina Specchia; Giovanna Meloni; Filippo Gherlinzoni; Claudio Giardini; Sadia Falcioni; Francesca Cuberli; Marco Gobbi; Barbara Sarina; Armando Santoro; Felicetto Ferrara; Marco Rocchi; Enrique M Ocio; Maria Dolores Caballero; Alessandro Isidori
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

3.  Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.

Authors:  J W Friedberg; D Neuberg; R M Stone; E Alyea; H Jallow; A LaCasce; P M Mauch; J G Gribben; J Ritz; L M Nadler; R J Soiffer; A S Freedman
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.

Authors:  Mani Ramzi; Mohsen Mohamadian; Reza Vojdani; Mehdi Dehghani; Habib Nourani; Maryam Zakerinia; Hoorvash Haghighinejad
Journal:  Exp Clin Transplant       Date:  2012-04       Impact factor: 0.945

5.  Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.

Authors:  E P Alessandrino; P Bernasconi; A Colombo; D Caldera; G Martinelli; P Vitulo; L Malcovati; C Nascimbene; M Varettoni; E Volpini; C Klersy; C Bernasconi
Journal:  Bone Marrow Transplant       Date:  2000-02       Impact factor: 5.483

6.  Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation.

Authors:  D W Milligan; M C Ruiz De Elvira; H J Kolb; A H Goldstone; G Meloni; A Z Rohatiner; P Colombat; N Schmitz
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

7.  BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.

Authors:  Jae-Cheol Jo; Byung Wook Kang; Geundoo Jang; Sun Jin Sym; Sung Sook Lee; Ja Eun Koo; Jong Wook Kim; Shin Kim; Jooryung Huh; Cheolwon Suh
Journal:  Ann Hematol       Date:  2007-08-21       Impact factor: 3.673

8.  High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.

Authors:  E H Wang; Y A Chen; S Corringham; A Bashey; P Holman; E D Ball; E Carrier
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

9.  [Non-Hodgkin's malignant lymphoma. Therapeutic value of autologous bone marrow transplantation].

Authors:  N C Gorin; A Najman; L Douay; C Salmon; R David; J Stachowiak; Y Parlier; M Oppenheimer; D Lecomte; M Lopez
Journal:  Presse Med       Date:  1983-09-10       Impact factor: 1.228

10.  Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS.

Authors:  Atul Sharma; Smita Kayal; Sobuhi Iqbal; Prabhat Singh Malik; Vinod Raina
Journal:  Springerplus       Date:  2013-09-26
View more
  2 in total

Review 1.  Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.

Authors:  Parastoo B Dahi; Hillard M Lazarus; Craig S Sauter; Sergio A Giralt
Journal:  Bone Marrow Transplant       Date:  2018-11-02       Impact factor: 5.174

2.  The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.

Authors:  Ramona Wullenkord; Philipp Berning; Anna-Lena Niemann; Klaus Wethmar; Sarah Bergmann; Mathias Lutz; Christoph Schliemann; Rolf Mesters; Torsten Keßler; Norbert Schmitz; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Ann Hematol       Date:  2021-09-03       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.